Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRED-loss Study
DRKS00037794Phase 4Recruiting
- Sponsor
- Klinik Barmelweid
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in Sleep-related eating disorder (SRED), sponsored by Klinik Barmelweid. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
Sleep-related eating disorder (SRED)
Beyond the preview
Go deeper on DRKS00037794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00037794.